• Just like a chameleon utilizing its
    colored pigments and crystals to
    adapt to its surroundings,
    we proactively pioneer and adapt to
    the everchanging NGS markets with
    our cutting-edge technology to
    support our customer’s needs.

CELEMICS' News & Events

View the various news of Celemics

Celemics bags $800K deal to supply gene expression profilers to Firalis SA


  • DateOct. 28 2020

Celemics bags $800K deal to supply gene expression profilers to Firalis SA  


Celemics has signed a $800,000 contract to supply its Next-Generation Sequencing (NGS)-based gene expression profilers for neurodegenerative disease to Firalis S.A., a France-based developer and provider of biomarker diagnostic products.

Shares of Kosdaq-listed Celemics traded a tad higher in the morning session on Wednesday.


According to its disclosure on Wednesday, Celemics will provide Firalis with NeuroMICS products for PAXgene/PBMC and Plasma/Saliva until 2022. The deal value represents about 18 percent of Celemics’ revenue last year.


NeuroMICS™ identifies and quantifies more than 5,000 brain tissue-specific long non-coding RNAs (lncRNAs) in peripheral blood samples that can serve as biomarkers to characterize patients with early-stage neurodegenerative disorders such as Alzheimer`s disease.


NeuroMICS features high-accuracy results based on Celemics` know-how in manufacturing NGS products for 10 years and its unique rebalancing and target capture technology. It can analyze about 5,000 types of lncRNAs at once, providing a more efficient and cost-effective approach than conventional methods, according to the company.


NeuroMICS is Celemics` second NGS-based product to be delivered to Firalis after a similar deal over FiMICS, an NGS-based product to quantify cardiac-enriched lncRNAs in 2018.


The availability of the lncRNA panel opens a window for new therapeutics and personalized medicine tools for diverse diseases, experts say.